Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind trial of abatacept or infliximab plus methotrexate versus placebo plus methotrexate in rheumatoid arthritis
2004-000922-59Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Abatacept + methotrexate, Infliximab + methotrexate and Placebo + methotrexate (3 arms). Primary endpoint: Primary endpoint: change in DAS28 for abatacept vs placebo at 6 months. Started Oct 2004; status: completed.
02
Drugs
abataceptinfliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2004-000922-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000922-59.